Pegfilgrastim

Pegfilgrastim
Systematic (IUPAC) name
	N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
Clinical data
Trade names	originally Neulasta, other brand names worldwide
AHFS/Drugs.com	monograph
MedlinePlus	a607058
Pregnancy; category	US: C (Risk not ruled out); ;
Legal status	US: ℞-only;
Pharmacokinetic data
Biological half-life	15–80 hrs
Identifiers
CAS Number	208265-92-3
ATC code	L03AA13 (WHO)
IUPHAR/BPS	6969
DrugBank	DB00019
UNII	3A58010674
KEGG	D06889
ChEMBL	CHEMBL1201568
Chemical data
Formula	C845H1343N223O243S9 + PEG
Molecular mass	39,000 g/mol
(what is this?) (verify)

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).^[2]

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.^[3]

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).^[4]^[3]

References

↑ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
↑ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–137.
↑ ^3.0 ^3.1 Drugs.com: Pegfilgrastim
↑ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, p. 139, 158.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.